Monday : The pharmaceutical firm Regeneron announced it entered in the stage of its human clinical trials investigating a drug to both treat and prevent COVID-19.
The drug, called REGN-COV2,and this drug is a combination of two antibodies that block the coronavirus’ “spike protein” which it uses to invade human cells.
The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus — for example through a person in their household.
This trial is a joint effort of the US National Institute of Allergy and Infectious Diseases (NIAID) , and is expected to enroll around 2,000 patients in the U.S
Regeneron President George Yancopoulos said, “We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an antiviral antibody cocktail that could be available much sooner than a vaccine.
At the same time, Regeneron announced it was moving to the final stages of a trial to determine the drug cocktail’s ability to treat both hospitalized and non-hospitalized COVID-19 patients.
With preliminary data expected later this summer, This will involve around 1,850 hospitalized and 1,050 non-hospitalized patients in the US, Brazil, Mexico and Chile.
Last year, a triple antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.